Clarus Therapeutics
Latest round
- Series C
Last raised
- Nov 2007
Total raised
- $8M
Investors
- 2
About Clarus Therapeutics
Founded in 2003 and headquartered in Northbrook, US, Clarus Therapeutics specializes in hormone therapy, particularly oral testosterone replacement therapy. Bob Dudley serves as the CEO.Clarus Therapeutics specializes in delivering innovative therapeutic solutions to address various health challenges, with a particular focus on hormone therapy. Their flagship product, an oral testosterone replacement therapy, is designed to treat men with testosterone deficiency, enhancing their quality of life by alleviating symptoms associated with low testosterone levels, such as fatigue, reduced libido, and mood disturbances. The company aims to improve patient adherence through its convenient oral dosing, providing an alternative to traditional injectable therapies. Clarus Therapeutics primarily serves a client base that includes healthcare providers, endocrinologists, and urologists, as well as pharmacies that dispense their products.Clarus Therapeutics generates revenue through direct sales of its oral testosterone therapy to healthcare providers and patients. The company employs a B2B transaction structure, where pharmacies purchase the product in bulk, subsequently offering it to end consumers. The pricing strategy for their flagship product is set to reflect its value in addressing testosterone deficiency, with structured payments based on negotiated terms with healthcare providers and pharmacies. Through these partnerships, Clarus Therapeutics is able to reach a wide audience of patients and healthcare professionals, positioning itself as a critical player in the hormone therapy market.00 mn to support growth initiatives for its product, JATENZO, which includes direct-to-consumer advertising and expansion of its R&D pipeline. The company aims to develop and launch new products to further its offerings in hormone therapy. Additionally, there are plans to expand into new markets, although specific regions have not been disclosed.
Who invested in Clarus Therapeutics
2 investors across 2 rounds
See all investors in Clarus Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Clarus Therapeutics
Who invested in Clarus Therapeutics?
Clarus Therapeutics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Clarus Therapeutics raised?
Clarus Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Clarus Therapeutics last raise money?
Clarus Therapeutics's most recent round on record is a Series C, in Nov 2007.
What does Clarus Therapeutics do?
Founded in 2003 and headquartered in Northbrook, US, Clarus Therapeutics specializes in hormone therapy, particularly oral testosterone replacement therapy.
Where is Clarus Therapeutics headquartered?
Clarus Therapeutics is headquartered in Northbrook, US.
Which VCs invest in companies like Clarus Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Clarus Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Clarus Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.